Investors

Northwest Clinical Trials Investor Information

Market Analysis
By 2020, the pharmaceutical market is anticipated to more than double to $1.3 trillion.

Trends
National spending on clinical trials was nearly $24 billion in 2005. By 2006 this number will rise to $25.6 billion and then $32.1 billion in 2011, an average annual growth rate (AAGR) of 4.6%. In 2005, biotechnology and pharmaceutical companies spent approximately $51 billion on research and development efforts, with $21 billion (41%) spent on clinical trials. In comparison, government contributions to clinical trials were considerably smaller. The National Institutes of Health spent $2.9 billion on clinical trials in 2005 and budgeted $3.0 billion for 2006.

Total funding for 2005 was $24.4 billion. In 2006 this number will rise to $26 billion and in 2011 to $32.6 billion, an AAGR of 4.6%

The number of clinical trials performed in 2005 was 8,386. BCC Research predicts this number will reach almost 10,000 by 2006. At an AAGR of 5.8%, the number of clinical trials performed in 2011 will reach more than 13,000.

 

U.S. Sponsored clinical Trials Market, 2003-2011($Billions)

Business Strategy
Northwest Clinical Trials, Inc. will expand clinical trial operations through strategic positioning in established research communities to ensure continued sustainable growth. The companys goals include utilizing existing industry relationships to develop and enhance multi-site trial allocation to expand revenue base; develop new relationships with key pharmaceutical groups based on extensive clinical trial experience and offer high-quality data procurement, and continuous upgrading of our proven site-management model to ensure profitability in any market.
 

The company maintains a clear vision of objectives through weekly scheduled meetings with executive management to monitor benchmarks and plan upcoming projects with special attention devoted to site-specific strengths and fiscal goals. The flexibility of the early phase units will allow NCT to offer clients the ability to complete vital assessments of new compounds with efficiency to determine the products viability prior to launching multi-million-dollar development programs.
 

In addition to the current site in Boise, Idaho, over the next three years four sites will be opened and profitable. Potential site locations may include, but are not limited to, Seattle, WA, Spokane, WA, and Portland, OR. and Cincinnati, OH. Additional sites may be added on an annual basis following the initial three-year period.
 

Each new site will open with five ongoing studies originating from the Boise site. Following start-up, three late-phase studies will be added each month to optimize staff workflow while minimizing risk of data-integrity issues. One early-phase study will be completed per quarter. For each site, additional staffing will be added at necessary growth milestones. Site production goals are to maintain 36 ongoing late-phase studies per month and a minimum of four early-phase studies per year.
New sites will be developed after extensive demographic research and identification of key staff has been established. This may take the form of existing site acquisition, but only after careful consideration of current site status and profitability is established.